Phase II of doxorubicin/taxol in metastatic breast cancer

Claudia Pazos,E. Mickiewicz,María Rosa Di Notto,Federico Cóppola,Mónica Ventriglia,Silvia Jovtis,Luis Balbiani,Daniel Lewi,Mónica Rondinón,G. Temperley,Mariana Trigo,Ana María Bertoncín,Pascual Mr,G. Uranga,Eduardo Cazap,Simónla Breier,Sergio Grasso,Roberto Estévez,Eduardo Triguboff,A. Alvarez,Albertoi Suárez

Phase II of doxorubicin/taxol in metastatic breast cancer

1999

Purpose. To assess the response rate, survival, and toxicity of Taxol®(paclitaxel) as 1‐h infusion plus doxorubicin as first‐line treatment for patients with metastatic breast cancer (MBC).

Keywords:

Mammary gland
Cancer research
Doxorubicin
Cancer
Endocrinology
Paclitaxel
Metastatic breast cancer
Medicine
Internal medicine
Chemotherapy
Toxicity
Drug interaction

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations